Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 14;32(2):156-161.e3.
doi: 10.1016/j.chom.2023.12.010. Epub 2024 Jan 10.

Memory T cells effectively recognize the SARS-CoV-2 hypermutated BA.2.86 variant

Affiliations
Free article

Memory T cells effectively recognize the SARS-CoV-2 hypermutated BA.2.86 variant

Thomas R Müller et al. Cell Host Microbe. .
Free article

Abstract

T cells are critical in mediating the early control of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) breakthrough infection. However, it remains unknown whether memory T cells can effectively cross-recognize new SARS-CoV-2 variants with a broad array of mutations, such as the emergent hypermutated BA.2.86 variant. Here, we report in two separate cohorts, including healthy controls and individuals with chronic lymphocytic leukemia, that SARS-CoV-2 spike-specific CD4+ and CD8+ T cells induced by prior infection or vaccination demonstrate resilient immune recognition of BA.2.86. In both cohorts, we found largely preserved SARS-CoV-2 spike-specific CD4+ and CD8+ T cell magnitudes against mutated spike epitopes of BA.2.86. Functional analysis confirmed that both cytokine expression and proliferative capacity of SARS-CoV-2 spike-specific T cells to BA.2.86-mutated spike epitopes are similarly sustained. In summary, our findings indicate that memory CD4+ and CD8+ T cells continue to provide cell-mediated immune recognition to highly mutated emerging variants such as BA.2.86.

Keywords: BA.1; BA.2.86; SARS-CoV-2; T cells; cellular immunity.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests A.S. is a consultant for AstraZeneca Pharmaceuticals; Calyptus Pharmaceuticals, Inc; Darwin Health; EmerVax; EUROIMMUN; F. Hoffman-La Roche Ltd; Fortress Biotech; Gilead Sciences; Granite Bio.; Gritstone Oncology; Guggenheim Securities; Moderna; Pfizer; RiverVest Venture Partners; and Turnstone Biologics. A.G. is a consultant for Pfizer. A.S. has filed for patent protection for various aspects of T cell epitope and vaccine design work. M.B. is a consultant and has received honoraria from Oxford Immunotec, MSD, BMS, Pfizer, and Mabtech. S.A. has received honoraria for lectures and educational events, not related to this work, from Gilead, AbbVie, MSD, and Biogen and reports grants from Gilead and AbbVie.

Supplementary concepts

LinkOut - more resources